Menu Search
Equities

Resonance Health Ltd

RSHTF:PKC

Resonance Health Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Resonance Health Limited is an Australia-based MedTech company. The Company specializes in the development and delivery of non-invasive medical imaging software and services. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.

  • Revenue in AUD (TTM)8.80m
  • Net income in AUD169.31k
  • Incorporated1987
  • Employees18.00
  • Location
    Resonance Health LtdGround Floor, SE 2 141 Burswood RoadPERTH 6100AustraliaAUS
  • Phone+61 89286-5300
  • Fax+61 89286-5399
  • Websitehttps://www.resonancehealth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RHT:ASX since
announced		Transaction
value
TrialsWest Pty LtdAnnounced02 Apr 202402 Apr 2024Announced-45.71%5.19m
Data delayed at least 20 minutes, as of Nov 13 2024 23:59 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.